News By Tag
* Universal Influenza Vaccine
* More Tags...
News By Location
BiondVax to Start Second Phase II Clinical Trial for Universal Flu Vaccine
BiondVax Announces Receipt of IRB Ethics (“Helsinki”) Committee Approvals for the Initiation of Second Phase II Clinical Trial for Universal Influenza Vaccine. The trial will start in October 2011 with 120 participants over the age of 65.
Ness Ziona, Israel – 29 August 2011 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a universal influenza vaccine, today announced that it has received the approvals of the Ethics (“Helsinki”)
The principal investigators conducting the clinical trial will be Prof. Yoseph Caraco, Director of the Hadassah Clinical Research Center (CRC) and Dr. Jacob Atsmon, Director of the Ichilov CRC.
The trial is designed to include a total of 120 participants, both male and female, 65 years of age and older. Screening of the potential participants will commence immediately, with the first administrations of the vaccine expected to take place in October 2011. The Company expects to be able to report headline results from this trial by the end of the first quarter of 2012.
Dr. Tamar Ben-Yedidia, BiondVax’s Chief Scientific Officer, said, “We are very pleased to have received the necessary approvals for the initiation of our second Phase II clinical trial, which follows the successful completion of our first Phase II trial a few months ago. We are looking forward to continuing our progress towards the successful development of the world’s first truly universal influenza vaccine.”
For further information, please contact:
Public Relations Consultant
Tel: +972 9 899 5813
Mobile: +972 50 799 1121
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals (“the Company”), a publicly-traded company (TASE: BNDX) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine, the Multimeric-001 vaccine, designed to provide multi-season and multi-strain protection against all human influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains.
BiondVax’s innovative technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.
BiondVax has successfully concluded one Phase IIa clinical trial, as well as two Phase I/II trials, in which the Multimeric-001 Universal Flu Vaccine was shown to be safe and immunogenic. The Company is now preparing for further Phase II clinical trials to be conducted in 2011 and 2012.
For further information on BiondVax, please visit www.biondvax.com
# # #
BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDK) based in Rehovot, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine with the potential to provide protection against most human influenza virus strains.